Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert H Vonderheide

Showing results (1-10 of 203) with videos related to

Pageof 21
Sort By:
Med (New York, N.Y.)|July 15, 2023
Cancer vaccines are back, revitalizedRobert H Vonderheide
Nature Medicine|October 8, 2015
CD47 blockade as another immune checkpoint therapy for cancerRobert H Vonderheide
Oncogene|February 19, 2002
Telomerase as a universal tumor-associated antigen for cancer immunotherapyRobert H Vonderheide
Cancer Cell|April 11, 2018
The Immune Revolution: A Case for Priming, Not CheckpointRobert H Vonderheide
Cancer Cell|May 15, 2014
Tumor-promoting inflammatory networks in pancreatic neoplasia: another reason to loathe KrasRobert H Vonderheide
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2026
Influence of tumor-draining lymph nodes on immunotherapy: lymphadenectomy may have its limitsRobert H Vonderheide
Biochimie|August 25, 2007
Prospects and challenges of building a cancer vaccine targeting telomeraseRobert H Vonderheide
Discovery Medicine|December 21, 2007
Universal tumor antigens for cancer vaccination: targeting telomerase for immunopreventionRobert H Vonderheide
Annual Review of Medicine|August 15, 2019
CD40 Agonist Antibodies in Cancer ImmunotherapyRobert H Vonderheide
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Prospect of targeting the CD40 pathway for cancer therapyRobert H Vonderheide
Pageof 21

Showing results (1-10 of 203) with videos related to

Sort By:
Pageof 21
Med (New York, N.Y.)|July 15, 2023
Cancer vaccines are back, revitalizedRobert H Vonderheide
Nature Medicine|October 8, 2015
CD47 blockade as another immune checkpoint therapy for cancerRobert H Vonderheide
Oncogene|February 19, 2002
Telomerase as a universal tumor-associated antigen for cancer immunotherapyRobert H Vonderheide
Cancer Cell|April 11, 2018
The Immune Revolution: A Case for Priming, Not CheckpointRobert H Vonderheide
Cancer Cell|May 15, 2014
Tumor-promoting inflammatory networks in pancreatic neoplasia: another reason to loathe KrasRobert H Vonderheide
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2026
Influence of tumor-draining lymph nodes on immunotherapy: lymphadenectomy may have its limitsRobert H Vonderheide
Biochimie|August 25, 2007
Prospects and challenges of building a cancer vaccine targeting telomeraseRobert H Vonderheide
Discovery Medicine|December 21, 2007
Universal tumor antigens for cancer vaccination: targeting telomerase for immunopreventionRobert H Vonderheide
Annual Review of Medicine|August 15, 2019
CD40 Agonist Antibodies in Cancer ImmunotherapyRobert H Vonderheide
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Prospect of targeting the CD40 pathway for cancer therapyRobert H Vonderheide
Pageof 21